Le Lézard
Classified in: Health, Business
Subjects: TNM, NPT

NUWAY Alliance Acquires The Gables Women's Treatment program


MINNEAPOLIS, March 25, 2020 /PRNewswire/ -- After continuously serving chemically dependent women since 1983 under the leadership of June Davis and Nancy Stofferahn, The Gables has reached an agreement to transfer ownership through a sale of its assets to the non-profit NUWAY Alliance. The purchase agreement will coincide with the sale of the residence located at 604 5th Street SW Rochester, Minnesota.

The Gables has been the premier residential recovery program for women in Rochester since its founding. Having a singular mission of serving women with addictions in a respectful and dignified manner aligns philosophically and clinically with NUWAY's mission. NUWAY®, the extended care treatment arm of NUWAY Alliance, recently opened a 30-bed women's treatment facility on Stevens Avenue in South Minneapolis. Acquiring The Gables doubles NUWAY's residential women's treatment capacity. "NUWAY Alliance couldn't be more proud to be selected by June and Nancy to continue their legacy of unwavering service to women afflicted with substance use disorders," said John Miller, NUWAY Alliance VP of Strategic Growth.

The Gables will become a subsidiary of the non-profit NUWAY Alliance, a recently established management company. NUWAY Alliance provides strategy, operations, marketing, finance, and human resource leadership and expertise to behavioral healthcare organizations. NUWAY®, the extended care treatment arm of NUWAY Alliance, operates facilities in Minneapolis, St. Paul, Duluth, and Rochester, and Cochran Recovery Services in Hastings. The deal is expected to close in May of this year, pending standard regulatory approvals.

For more information, contact Monique Bourgeois, NUWAY Chief Community Relations Officer, at 651-964-3680.

 

SOURCE NUWAY


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: